The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing improved cancer immunotherapy treatments. UW–Madison researchers have engineered a novel nanoparticle that elicits an improved immune response in select melanomas for significant tumor suppression.

Cancer immunotherapy – a therapy that stimulates and employs the body’s own immune system – is one of the most promising new approaches for treating cancer. Despite its tremendous potential, it shows limited effectiveness on patients with immunogenically “cold” tumors, as these tumors remain “hidden” from immune cells. Radiation therapy has been shown to improve the immunotherapy by turning a “cold” tumor into a “hot” one, thereby highlighting tumor cells for immune cell recognition. Significant effort has gone into stimulating immune cells to recognize tumor cells, but available methods are limited and often result in modest therapeutic benefit.

Click here to read the full article.